ID: ALA4091555

Max Phase: Preclinical

Molecular Formula: C26H25Cl2N5O2S

Molecular Weight: 542.49

Molecule Type: Small molecule

Representations

Canonical SMILES:  CC(C)/C(N)=N\C(=N/S(=O)(=O)c1ccc(Cl)cc1)N1CC(c2ccccc2)C(c2ccc(Cl)cc2)=N1

Standard InChI:  InChI=1S/C26H25Cl2N5O2S/c1-17(2)25(29)30-26(32-36(34,35)22-14-12-21(28)13-15-22)33-16-23(18-6-4-3-5-7-18)24(31-33)19-8-10-20(27)11-9-19/h3-15,17,23H,16H2,1-2H3,(H2,29,30,32)

Standard InChI Key:  UUXLYMXFGLKIOY-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 542.49

Molecular Weight (Monoisotopic): 541.1106

AlogP: 5.56

#Rotatable Bonds: 5

Polar Surface Area: 100.48

Molecular Species: NEUTRAL

HBA: 3

HBD: 1

#RO5 Violations: 2

HBA (Lipinski): 7

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 2

CX Acidic pKa:

CX Basic pKa: 7.80

CX LogP: 5.74

CX LogD: 5.21

Aromatic Rings: 3

Heavy Atoms: 36

QED Weighted: 0.34

Np Likeness Score: -0.78

References

1. Iyer MR, Cinar R, Katz A, Gao M, Erdelyi K, Jourdan T, Coffey NJ, Pacher P, Kunos G..  (2017)  Design, Synthesis, and Biological Evaluation of Novel, Non-Brain-Penetrant, Hybrid Cannabinoid CB1R Inverse Agonist/Inducible Nitric Oxide Synthase (iNOS) Inhibitors for the Treatment of Liver Fibrosis.,  60  (3): [PMID:28085283] [10.1021/acs.jmedchem.6b01504]

Source

Source(1):

• Scientific Literature